Formoterol Fumarate
Phase 3Small molecule
AstraZenecaFormoterol Fumarate is a small molecule that works as a Beta-2 Adrenergic Receptor Agonist.[2] It is being investigated across 4 indications, with its most advanced program in Phase 3.[1]
Formoterol Fumarate is one of 27 small molecule programs targeting Chronic Bronchitis. It is currently in Phase 3.
4
Indications
42
Total Trials
2
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
16 competitors in Emphysema
#DrugCompanyPhaseTrials
1Viagra
VViatris Specialty LLC
Approved
Foradil
ViatrisApproved
Serevent
GGlaxo Dba Glaxosmithkline
Approved
Pulmicort
SSalix
Approved
Advil
KKenvue Brands
Approved
Formoterol Fumarate
AstraZenecaPhase 3
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Veramyst
GSKPreclinical
Spiriva
Boehringer IngelheimPreclinical
Spiriva
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Obstructive Pulmonary Disease11 trials
Show 8 more trials
Asthma8 trials
Replication of the P04334 Asthma Trial in Healthcare Claims Data
Completed·—··NCT04892758·10,288 enrolled
Efficacy and Safety5 trials
COPD5 trials
10 more indications
Complication1 trial
Perioperative Inhaled Therapy in Carcinological Thoracic Surgery in Patients at High Risk of Postoperative Pulmonary Complications
Recruiting·—·N/A·NCT06865040·266 enrolled
Function1 trial
Moderate to Severe COPD1 trial
RCT1 trial
Efficacy1 trial
MPA1 trial
COPD Exacerbation1 trial
Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD): A Phase IV, Prospective, Randomized, Blinded, Parallel-group Trial
Not yet recruiting·UUniversity of Tennessee Graduate School of Medicine·Approved·NCT07721922·280 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Formoterol Fumarate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Beta-2 Adrenergic Receptor Agonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company